Related Experiment Videos
Rapidly progressive glomerulonephritis after immunotherapy for cancer
M G Parker1, M B Atkins, A A Ucci
1Division of Nephrology, New England Medical Center, Boston, MA, USA.
Journal of the American Society of Nephrology : JASN
|April 1, 1995
Summary
Interleukin-2 and interferon-alpha combination therapy for metastatic renal cell carcinoma can cause severe kidney damage. This immune-enhancing treatment led to pauci-immune crescentic glomerulonephritis in one patient, highlighting potential renal risks.
Area of Science:
- Immunology
- Nephrology
- Oncology
Background:
- Cytokines like interleukin-2 (IL-2) and interferon-alpha (IFN-α) are utilized for cancer immune enhancement.
- These cytokines have been explored in experimental protocols for metastatic renal cell carcinoma (mRCC).